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1. Introduction 
Rupture of anterior cruciate ligament (ACL) is a common knee trauma which leads to 
anterior knee instability. The ACL has long been thought to have poor capacity for healing 
with suture repair. ACL reconstruction is the standard of care which can restore the knee 
stability of ACL deficit knee. Although ACL reconstruction is an excellent operation for 
restoring the sagittal plane stability of the knee, significant problems remain. Studies have 
demonstrated that remodeling of the graft usually takes longer than expected, and many 
patients develop arthritis after an ACL tear, even if they have a reconstruction, with rates as 
high as 78% reported at 14 years post-operatively (1).  
In ACL reconstruction, inflammation and necrosis of the graft can occur immediately after 
transplantation. The graft then undergoes revascularization and cellular repopulation 
from an extrinsic origin, followed by a remodeling period. In the early phase, the 
properties of the grafted tendon are deteriorated and do not recover to physiological 
levels even at 18 months after surgery (2). Therefore, the main goals of ACL 
reconstruction are to prevent the deterioration of grafted tendon and accelerate 
mechanical restoration of the deteriorated graft. New solutions are needed to accelerate 
and improve remodeling of tendon grafts. 
The ACL graft remodeling process is regulated by a complex growth factor network. Many 
growth factors have been evaluated for their ability to stimulate tendon and ligament 
healing in vitro and in vivo. In enhancing ligament repair, the most interesting candidates 
are insulin-like growth factor-I (IGF-I), transforming growth factor ┚1 (TGF┚1), vascular 
endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth 
factor (PDGF), and basic fibroblast growth factor (bFGF). PDGF and VEGF appear in the 
early stage of reconstruction, during the stage of graft maturing, the granular tissue becomes 
ligament-like tissue and both PDGF and VEGF are not able to be detected gradually, as the 
replacement, TGF┚1and other cytokines are involving in the reconstruction process to 
mature the ligament. TGF┚1 is the main cytokine for the maturing of ligament. Studies have 
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demonstrated improved cellular proliferation and migration as well as increased collagen 
production rates with the addition of growth factors. 
2. VEGF 
Angiogenesis is an essential step in the process of tendon healing and tendon graft 
remodeling, in which neovascularization prompts delivery of inflammatory cells, fibroblasts 
and growth factors to the wound site. VEGF plays an essential role in angiogenesis, 
regulating the activation, migration, and proliferation of endothelial cells in various 
pathological conditions. It is well-known that angiogenesis is an essential step in the healing 
process of tendon and tendon graft remodeling. Two studies found that VEGF therapy can 
enhance revascularization in the graft, as well as promoting the infiltration of fibroblasts 
after ACL reconstruction; however, it did not affect the mechanical properties of the in situ 
freeze-thawed ACL model (3). Furthermore, it decreased the stiffness of the grafted tendon 
with increased knee laxity, 12 weeks after ACL reconstruction in a sheep model (4). 
Yoshikawa et al. examined the effects of an application of VEGF to a hamstring graft in a 
sheep ACL reconstruction model and demonstrated that the linear stiffness of the VEGF-
treated graft was significantly lower than that of the PBS-treated group at 12 weeks (4). In 
this study, the stiffness of the VEGF165 group was higher than those of the control group at 
12 weeks, although there was no significant difference (P > 0.05). There are two possible 
reasons for this difference.  
In our study, the stiffness of the VEGF165 group was higher than those of the control 
group at 12 weeks, although there was no significant difference (5). There are two possible 
reasons for this difference. One is the method of applying this factor. In our study, the 
method was transfer of the VEGF165 gene, rather than the gene products. The secretion 
time and quantity of VEGF165 may be suitable for ACL graft remolding. The other 
possible reason is the use of BMSCs in our experiment. BMSCs have the capacity to 
differentiate into various mesenchymal lineages, including ligament, tendon, muscle, 
bone, cartilage and adipose tissue. Kanaya et al. reported that the intra-articular injection 
of BMSCs could accelerate the healing of partially torn knee ACLs in a rat model (6). Our 
study also demonstrated that the application of BMSCs is effective in enhancing collagen 
deposition and changing certain structural properties for improving tendon allograft 
remodeling after ACL reconstruction in a rabbit model (7). The exact reasons for the better 
healing observed in injured ACLs using BMSCs are uncertain. One possibility is that 
BMSCs directly differentiated into ligament fibroblasts within the healing environment. 
Alternatively, another possibility is that injected mesenchymal stromal cells directly 
contribute as a cellular source for ligament healing. BMSCs may also secrete a variety of 
growth factors, which may contribute to the activation and recruitment of local fibroblast 
precursors or enhance extracellular matrix synthesis.  
3. PDGF 
Many studies have also attempted to determine the effects of PDGF-BB on a ligament 
engineering system. It has been demonstrated that it promoted fibroblast proliferation, 
matrix synthesis, neovascularization, and mechanical properties. In our studies in the gene-
transfected group, more cells and blood vessels could be found at 3 weeks, and more 
collagen was synthesized in the ACL as compared with the control and MSCs group (7). 
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Similar to our findings were the results of a study by Nakamuraetal, which described an 
increased vascularity and enhanced collagen deposition in the wound of a patellar ligament 
afte rPDGF-B gene transfer in rats (8). 
The mechanisms by which PDGF affects ligament healing are complex. Kuroda et al. studied 
immunohistochemically the presence and the level of bFGF, TGF-ß, PDGFAA and PDGF-BB 
expression in a model of ACL reconstruction using a free patellar tendon autograft (9). They 
found that all tested growth factors were upregulated with a maximum expression at 3 
weeks and up to 60% of all cells were stained PDGF positive. PDGF is one of the most 
effective growth factors during tendon graft remodeling. 
Tendon grafts are exposed to the reduced PO2 of the intra-articular environment, Petersen 
et al. (10) showed that PDGF as well as hypoxia strongly enhanced VEGF secretion from 
tenocytes. Besides this VEGF-mediated angiogenetic effect, PDGF further more induces the 
synthesis of other growth factors, including IGF, and regulates the presence of other 
receptors (11). Therefore, it could be concluded that the expression of PDGF-BB by the small 
number of transfected cells may activate a cascade of PDGF-BB throughout the wound. 
Some researches (12) showed that there are some growth factors receptors such as PDGFR 
on the surface of MSCs. MSCs from bone marrow might have a better response to PDGF as 
compared with those from the ACL or MCL regarding proliferation and migration. Thus, it 
might be suggested that a tendon graft seeded with MSCs-PDGF-BB is more likely to 
promote MSCs or fibroblast proliferation and migration and accelerate graft tissue 
remodeling. 
The observations of Kuroda et al. also imply that if a growth factor is administered to the 
tendon graft, its tissue concentration should be highest around the third week to enhance 
the effect of the other intrinsical growth factors (9). In our study at 3 weeks, we found 
significantly higher vascularity in the PDGF-transfected grafts. The concentration of PDGF-
BB inarticular fluid from gene-transfected rabbit increased at 3 week, got to the highest 
point at 6 week and then dropped down. This rapid reduction in the level of their 
localization indicates that once the extrinsic cells infiltrate to the graft and revascularization 
is complete, these growth factors may have less significance for subsequent remodeling. 
Therefore, it is very important to find the appropriate time point for the administration of 
growth factors to promote healing. 
In vivo study by Hildebrand et al. demonstrated that the improvements in the MCL 
structural properties were dose-dependent to PDGF-BB (13).That is, a higher dose of PDGF-
BB improved more structural properties of the femur–MCL–tibia complex than a lower dose 
of PDGF-BB did. In both the MSCs group and gene-transfected group, although there are 
much more differences in morphology at the early stages, the structure of the ACL in the 
two groups have less significant differences at the later stages, especially at 12 weeks. For an 
ACL reconstruction model, we don’t know if the dosage we used was appropriate to 
maximally enhance graft remodeling, or this indicates that the growth fact or PDGF may 
have early effect on the ACL reconstruction and have less significance for subsequent 
remodeling. It is essential to find an appropriate dosage for ACL reconstruction. 
4. TGFβ1 
Many studies indicate that TGF┚1 plays a key role in the healing process of ligaments. 
TGF┚1 increased both collagen and non-collagenous protein synthesis by the introduction of 
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ACL fibroblasts (14, 15). Furthermore, it has also been shown to increase ACL fibroblast 
proliferation. TGF┚1 enhanced graft remolding in ACL reconstruction by inhibiting 
mechanical deterioration (16).  
In situ freeze-thawed ACL tissues, which were established as an autograft model, 
transfected with TGF┚1 and EGF, significantly reduced the increase in water content and 
cross-sectional area and reduced the deterioration of the ACL (17). However, the results 
were dose- and time-dependent, and of high cost. Furthermore, the clinical application of 
growth factors is hampered by delivery problems. Amiel et al. reported that a high dose of 
TGF┚1 inhibits proliferation of rabbit ACL fibroblasts (18). One study reported that an 
application of low-dose TGF┚1 mixed with fibrin sealant enhanced the remodeling process 
of the in situ freeze-thawed ACL, whereas a high dose of TGF┚1 had no effect (17). We 
demonstrated that TGF┚1 gene-modified BMSCs implanted within the Achilles allograft in 
ACL reconstruction significantly affects the biomechanical properties of the graft. Our 
results suggest that the transfer of the TGF┚1 gene, rather than the gene products, may be 
the most expeditious method of harnessing this factor for the purposes of accelerating ACL 
graft remolding (5). 
Our results showed that the ultimate failure load and the stiffness of the grafted tendon 
were significantly increased in the TGF┚1 treatment group compared with the VEGF165 and 
control groups at 6, 12 and 24 weeks after surgery. Meanwhile toluidine blue staining of the 
grafts appeared positive only in the TGF┚1 group at 12 weeks. ACL has different 
histological characteristics from medical collateral ligament (MCL), which is more cartilage-
like in nature. The normal ACL is positive to toluidine blue staining, so we hypothesized 
that TGF┚1 may promote early maturation of the graft. Histological examination and 
immunohistochemistry showed significantly enhanced cell infiltration and revascularization 
at 3, 6, and 12 weeks in the VEGF165 and the TGF┚1/VEGF165 groups. However, VEGF165 
cDNA-transduced BMSCs exhibited no significant effects on the mechanical properties of 
the ACL graft, while TGF┚1/VEGF165 cDNA-transduced BMSCs showed the best 
biomechanical properties of the ACL graft at 24 weeks after surgery. This work shows that 
the use of TGF┚1 and the co-expression of TGF┚1/VEGF165 of gene therapy may be useful 
for accelerating the remolding of the graft after ACL reconstruction. 
Previous study by Lee et al. demonstrated that VEGF and TGF┚1 were both expressed in 
ACL healing (18). We demonstrate here that the combination of TGF┚1 and VEGF165 gene 
has a synergistic effect on accelerating the remolding of the ACL graft, but few studies have 
defined the exact regulating mechanisms of these two growth factors during ligament 
healing. Several studies have demonstrated that together VEGF and TGF┚1 can enhance 
each the synthesis of one another (19, 20). These studies revealed that the mechanism of 
synergy is probably mediated through Smad3, HIF-1┙/┚, Smad3/4, PI3K/Akt or ERK1/2 
signaling pathways. 
5. The Effects of TGF-β1, VEGF165 transfer on achilles tendon healing 
The Achilles tendon itself is a dense, regular connective tissue consisting primarily of type I 
collagen and interspersed specializedmesenchymal cells (tenocytes) responsible for the 
maintenance of collagen structure. With respect to reconstruction of the tendon, there are 
three key factors which must be addressed: the cell, the fiber, and their arrangement. The 
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properties of the tendon matrix and its regulation by growth factors are largely 
uncharacterized. We examined the effects of implantation of BMSCs transduced with either 
the TGF-┚1, VEGF165, or both on experimentally injured Achilles tendons in a rabbit model 
in vivo (21).  
The maximum failure load, the tendon stiffness, and the elastic modular of the healing 
tendons were significantly increased in the TGF-┚1 and the co-expression treatment 
groups compared with the other treatment groups at one, two, four, and eight weeks after 
surgery. Moreover, there was evidence of accelerated remodeling of the lesion in response 
to TGF-┚1 and co-expression TGF-┚1/VEGF165 treatment, while the size of the ruptured 
callus was increased in the presence of VEGF165. Histological examination showed a 
much more organized and homogeneous pattern of collagen fibers at all time points in the 
lesions of the TGF-┚1 and the co-expression treatment groups. Both single fibrils and the 
collagen fibers had a greater diameter, with a higher degree of collagen crimp than the 
collagen of the other treatment groups. This was confirmed by Sirius red staining in 
conjunction with polarized light microscopy, which showed a higher shift of small 
yellow-green fibers to strong yellow-orange fibers after two, four, and eight weeks in the 
TGF-┚1 and the co-expression treatment groups. Immunohistochemistry showed more 
vessels after one, two, four, and eight weeks in the VEGF165 treatment group, but only a 
few vessels in the co-expression treatment group. There was also an earlier shift from 
fibroblasts to fibrocytes within the healing tendon, with fewer fat cells present in the 
tendons of the TGF-┚1 and the co-expression treatment groups compared with intact 
tendon. Thus treatment with TGF-┚1 transduced BMSCs resulted in a promising 
acceleration and improvement of tendon healing, particularly influencing early tissue 
regeneration, leading to quicker recovery and improved biomechanical properties of the 
Achilles tendon. However, VEGF165 transduced BMSCs exhibited a negative role. The 
angiogenesis effects of VEGF165 were diminished by TGF-┚1, while the collagen synthesis 
effects of TGF-┚1 were only slightly affected by VEGF165. The TGF-┚1 and VEGF165 
synthesized of BMSCs with gene transfer were evaluated by ELISA. However, the 
stimulation effect is very weak with heterologous gene transfer in contrast with 
homologous gene transfer. In terms of the fibroblasts, the mRNA expression of Collagen 
type I, type III and Fibronectin were evaluated. All showed significant increasing under 
the stimulation of TGF-┚1 or TGF-┚1/VEGF165 co-existing. Nevertheless, the fibroblasts 
stimulated by VEGF165 showed no difference with control. 
We demonstrated that gene modified BMSCs implanted within the tendon-repair site 
contributed to early tendon-healing following primary repair, and that growth factor 
signaling can regulate the mechanical properties of the tendon matrix by affecting tendon 
mass and architecture. These data provide a basis for future application of supplementary 
therapy of surgery for tendon and ligaments. Future studies determining the optimal 
growth factor(s), dose, and timing and site of administration are required, along with the 
interactions between different growth factors. 
6. Summary 
The effects of TGF-┚1, VEGF and PDGF on the remodeling of anterior cruciate ligament 
graft are different. PDGF, VEGF and TGF┚1transfected MSCs accelerated cellular infiltration 
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and enhanced collagen deposition in the graft. PDGF and VEGF promoted the angiogenesis 
of the graft, but did not show any improvement of the biomechanical nature of the graft. 
Only TGF┚1accerated the maturing of graft and improved the biomehchanical nature. 
TGF┚1 co–expression with VEGF165 in gene-transfected BMSCs could accelerate the 
remodeling of the reconstructed ligament. The cross-talk between TGF┚1 and VEGF165 has 
positive consequences, with TGF┚1/VEGF165-gene-transfected BMSCs could significantly 
promote angiogenesis of the reconstructed ligament, while achieving the best mechanical 
properties of the reconstructed ligament. However, the molecular mechanism that regulates 
these two growth factors during ligament healing still needs to be fully elucidated. The 
effects of other growth factors on the remodeling of ACL graft, such as IGF-1, bFGF, need 
further study. 
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